Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curt Furberg

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Lakartidningen|May 16, 2009
[A clear winner and two losers]Curt Furberg
Lakartidningen|February 6, 2004
[Alfadil--positive documentation when it comes to safety is missing]Curt Furberg
Lakartidningen|April 9, 2009
[ACCOMPLISH and the risks with company sponsored clinical trials]Curt Furberg
Lakartidningen|January 14, 2004
[Reduce prescription of expensive drugs without increased value]Curt Furberg
Current Controlled Trials in Cardiovascular Medicine|November 21, 2001
Current Controlled Trials in Cardiovascular Medicine: a new journal for a new age (http://cvm.controlled-trials.com)Curt Furberg, Bertram Pitt
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Are there fundamental deficiencies in the megatrial methodology?Desmond Julian, Curt Furberg
Neurology|May 10, 2014
Author ResponseSevil Yasar, Curt Furberg, Claudia Kawas, et al.
Lancet (London, England)|June 15, 2020
Questioning statin therapy for older patientsJohn Abramson, Curt Furberg, Nicholas Jewell, et al.
The American Journal of Cardiology|July 17, 2007
Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular diseaseAllan D Sniderman, Ingar Holme, Are Aastveit, et al.
The American Journal of Cardiology|March 28, 2006
Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?Ingmar Jungner, Allan D Sniderman, Curt Furberg, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Lakartidningen|May 16, 2009
[A clear winner and two losers]Curt Furberg
Lakartidningen|February 6, 2004
[Alfadil--positive documentation when it comes to safety is missing]Curt Furberg
Lakartidningen|April 9, 2009
[ACCOMPLISH and the risks with company sponsored clinical trials]Curt Furberg
Lakartidningen|January 14, 2004
[Reduce prescription of expensive drugs without increased value]Curt Furberg
Current Controlled Trials in Cardiovascular Medicine|November 21, 2001
Current Controlled Trials in Cardiovascular Medicine: a new journal for a new age (http://cvm.controlled-trials.com)Curt Furberg, Bertram Pitt
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Are there fundamental deficiencies in the megatrial methodology?Desmond Julian, Curt Furberg
Neurology|May 10, 2014
Author ResponseSevil Yasar, Curt Furberg, Claudia Kawas, et al.
Lancet (London, England)|June 15, 2020
Questioning statin therapy for older patientsJohn Abramson, Curt Furberg, Nicholas Jewell, et al.
The American Journal of Cardiology|July 17, 2007
Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular diseaseAllan D Sniderman, Ingar Holme, Are Aastveit, et al.
The American Journal of Cardiology|March 28, 2006
Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?Ingmar Jungner, Allan D Sniderman, Curt Furberg, et al.
Pageof 3